Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized-withdrawal study of JZP-258 in narcolepsy with cataplexy
NL-OMON46347Phase 3Active, not recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in narcolepsy and narcolepsy type 1 (NT1) comparing JZP-258 continuation with Placebo withdrawal arm (2 arms). Primary endpoint: Change in weekly number of cataplexy attacks. Started Oct 2018; status: active, not recruiting.
02
Drugs
sodium oxybate + calcium oxybate + potassium oxybate + magnesium oxybate
03
Conditions
narcolepsynarcolepsy type 1 (NT1)
Beyond the preview
Go deeper on NL-OMON46347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46347.